Mechanistic description
Low-micromolar systemic SCFA exposure is unlikely to directly drive substantia nigra alpha-synuclein clearance, but colon and enteric nervous system compartments experience much higher local exposure and may show reduced pS129-alpha-syn, lower seeding pressure, and delayed gut-to-brain propagation. This is the strongest translationally credible hypothesis because it matches exposure reality and explains why dietary or microbiome interventions could matter without requiring pharmacologic brain concentrations.
Mechanism / pathway
- SNCA
- neurodegeneration
Evidence for (7)
Human circulating SCFAs are low, supporting the idea that any physiologic effect is more likely to occur in gut or ENS compartments than through direct CNS exposure.
Sodium butyrate reduced colonic and nigral alpha-syn pathology in a rotenone model, consistent with a possible gut-origin effect even though dosing was pharmacologic.
R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation.
Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.
MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
Evidence against (2)
Existing studies do not establish a temporal gut-first sequence or direct aggregate clearance kinetics under physiologic exposure.
Low plasma SCFA measurements support exposure skepticism but do not themselves prove gut-first causality.
Evidence matrix
Supporting
- Human circulating SCFAs are low, supporting the idea that any physiologic effect is more likely to occur in gut or ENS compartments than through direct CNS exposure. PMID:35091760
- Sodium butyrate reduced colonic and nigral alpha-syn pathology in a rotenone model, consistent with a possible gut-origin effect even though dosing was pharmacologic. PMID:36761177
- R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation. PMID:40143425 · 2025 · Autophagy
- Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy. PMID:33323315 · 2021 · Trends Biochem Sci
- MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease. PMID:38041169 · 2023 · Mol Neurodegener
- Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. PMID:35287553 · 2022 · Autophagy
- α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. PMID:33682798 · 2021 · JCI Insight
Contradicting
- Existing studies do not establish a temporal gut-first sequence or direct aggregate clearance kinetics under physiologic exposure. PMID:36761177
- Low plasma SCFA measurements support exposure skepticism but do not themselves prove gut-first causality. PMID:35091760
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund signals
from 1 contributing personas in log-odds space, weighted
by uniform. Prior 50%.
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-f…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-308757f973
@misc{scidex_hypothesis_h308757f,
title = {Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-f…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-308757f973},
note = {SciDEX artifact hypothesis:h-308757f973}
}